Cafusertib

Drug Profile

Cafusertib

Alternative Names: Cafusertib HCl; Cafusertib hydrochloride

Latest Information Update: 11 Mar 2016

Price : $50

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Protein-serine-threonine kinase inhibitors; Proto-oncogene protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 11 Mar 2016 Phase-I development is ongoing in China
  • 30 Nov 2014 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (IV)
  • 01 May 2014 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top